Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer.

ABSTRACT: Optimal debulking followed by chemotherapy is the standard treatment of managing late-stage ovarian cancer, but chemoresistance is still a major problem. In this study, we compared expression profiles of primary tumor tissue from five long-term (>8 years) and five short-term (<2 years) ovarian cancer survivors and identified clusterin as one of the genes that were significantly up-regulated in short-term survivors. We then evaluated the prognostic significance of clusterin and its possible correlation with chemoresistance in ovarian cancer by immunohistostaining of clusterin in 62 tumor samples from patients with stage III, high-grade serous ovarian cancer. After adjusting for debulking status and age, Cox regression analyses showed that high levels of clusterin expression correlate with p

SUBMITTER: Park DC 

PROVIDER: S-EPMC2517641 | biostudies-literature | 2008 Sep

REPOSITORIES: biostudies-literature